Regeneron Pharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $829.4565
- Today's High:
- $837.3
- Open Price:
- $835.49
- 52W Low:
- $668
- 52W High:
- $847.5
- Prev. Close:
- $833.53
- Volume:
- 284041
Company Statistics
- Market Cap.:
- $90.49 billion
- Book Value:
- 225.944
- Revenue TTM:
- $12.67 billion
- Operating Margin TTM:
- 34.88%
- Gross Profit TTM:
- $7.02 billion
- Profit Margin:
- 33.93%
- Return on Assets TTM:
- 9.55%
- Return on Equity TTM:
- 19.23%
Company Profile
Regeneron Pharmaceuticals Inc had its IPO on 1991-04-02 under the ticker symbol REGN.
The company operates in the Healthcare sector and Biotechnology industry. Regeneron Pharmaceuticals Inc has a staff strength of 12,256 employees.
Stock update
Shares of Regeneron Pharmaceuticals Inc opened at $835.49 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $829.46 - $837.3, and closed at $832.77.
This is a -0.09% slip from the previous day's closing price.
A total volume of 284,041 shares were traded at the close of the day’s session.
In the last one week, shares of Regeneron Pharmaceuticals Inc have increased by +0.14%.
Regeneron Pharmaceuticals Inc's Key Ratios
Regeneron Pharmaceuticals Inc has a market cap of $90.49 billion, indicating a price to book ratio of 3.8097 and a price to sales ratio of 5.8086.
In the last 12-months Regeneron Pharmaceuticals Inc’s revenue was $12.67 billion with a gross profit of $7.02 billion and an EBITDA of $4.82 billion. The EBITDA ratio measures Regeneron Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Regeneron Pharmaceuticals Inc’s operating margin was 34.88% while its return on assets stood at 9.55% with a return of equity of 19.23%.
In Q2, Regeneron Pharmaceuticals Inc’s quarterly earnings growth was a positive 13.8% while revenue growth was a positive 10.5%.
Regeneron Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 17.7936
- Trailing PE
- 21.9062
- PEG
- 9.0135
Its diluted EPS in the last 12-months stands at $38.05 per share while it has a forward price to earnings multiple of 17.7936 and a PEG multiple of 9.0135. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Regeneron Pharmaceuticals Inc’s profitability.
Regeneron Pharmaceuticals Inc stock is trading at a EV to sales ratio of 5.6422 and a EV to EBITDA ratio of 12.0691. Its price to sales ratio in the trailing 12-months stood at 5.8086.
Regeneron Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $30.66 billion
- Total Liabilities
- $3.10 billion
- Operating Cash Flow
- $-2386900000.00
- Capital Expenditure
- $133.90 million
- Dividend Payout Ratio
- 0%
Regeneron Pharmaceuticals Inc ended 2024 with $30.66 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $30.66 billion while shareholder equity stood at $24.02 billion.
Regeneron Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $3.10 billion in other current liabilities, 100000.00 in common stock, $25.09 billion in retained earnings and $0 in goodwill. Its cash balance stood at $1.94 billion and cash and short-term investments were $8.93 billion. The company’s total short-term debt was $0 while long-term debt stood at $1.98 billion.
Regeneron Pharmaceuticals Inc’s total current assets stands at $16.92 billion while long-term investments were $6.33 billion and short-term investments were $6.99 billion. Its net receivables were $5.12 billion compared to accounts payable of $547.30 million and inventory worth $2.01 billion.
In 2024, Regeneron Pharmaceuticals Inc's operating cash flow was $-2386900000.00 while its capital expenditure stood at $133.90 million.
Comparatively, Regeneron Pharmaceuticals Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $832.77
- 52-Week High
- $847.5
- 52-Week Low
- $668
- Analyst Target Price
- $871.95
Regeneron Pharmaceuticals Inc stock is currently trading at $832.77 per share. It touched a 52-week high of $847.5 and a 52-week low of $847.5. Analysts tracking the stock have a 12-month average target price of $871.95.
Its 50-day moving average was $774.65 and 200-day moving average was $762.6 The short ratio stood at 2.31 indicating a short percent outstanding of 0%.
Around 254.2% of the company’s stock are held by insiders while 8944.7% are held by institutions.
Frequently Asked Questions About Regeneron Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.